zacks.com / .zacks-com / Page 9

Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.

With healthy fundamentals and a unique business model, UI appears to be a solid investment option at the moment.

NVIDIA isn't just a leader in one country or one region-it's making its mark all over the world.

In Trump's second term, tech giants like GOOGL, MSFT, META and AAPL face tough regulations on AI, antitrust and privacy.

With FDX looking to cut costs in the face of weak demand, we aim to assess the investment worthiness of the stock currently.

TUYA's diverse portfolio and strong clientele make the stock lucrative. However, stretched valuation and macro headwinds can be risky.

As consumer preferences continue to evolve toward health and value-driven purchases, TSN, STZ, FRPT, PG and CL are well-placed for growth in 2025.

MS stock gains 32.4% this year. With the revival of global M&As, read on to know how 2025 will be for the stock and what investors should do.

GD secures a contract to provide engineering, technical, design agent and planning yard support for operational strategic and attack submarines.

Gentex plans to acquire VOXX in an all-cash deal valued at $7.50 per share. Ford and SK On secure $9.6 billion EV battery loan.